drugset
drugset / Trial / NCT05496205

A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers

NCT05496205 ↗

Phase 1 Completed 104 enrolled iN Therapeutics Co., Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

A First-in-Human, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of iN1011-N17 after Oral Administration in Healthy Volunteers.

Timeline

Start
2020-09-30
Primary completion
2023-10-08
Completion
2023-10-08

Drugs

EvaluationDrugModalityDoseRoute
Subject iN1011-N17 Unknown — Oral

Indications

chronic pain syndrome neuropathy, painful osteoarthritis postherpetic neuralgia